原创《醒脑静联合尼莫地平对高血压脑出血患者NIHSSADL评分影响》：本论文为免费优秀的关于尼莫地平论文范文资料，可用于相关论文写作参考。
【摘 要】 目的 研究醒脑静联合尼莫地平对高血压脑出血（HCH）患者美国国立卫生研究院卒中量表（NIHSS）及日常生活能力量表（ADL）评分的影响.方法 68例HCH患者, 随机分为对照组和观察组, 各34例.对照组患者给予醒脑静进行常规治疗, 观察组患者给予醒脑静联合尼莫地平治疗, 均治疗4周.比较两组患者治疗前后的NIHSS评分以及出院3个月后的日常生活能力.结果 治疗4周后, 观察组患者NIHSS评分（6.92±6.84）分低于治疗前的（17.51±3.26）分, 对照组患者NIHSS评分（11.42±7.31）分低于治疗前的（17.60±2.73）分, 且观察组的NIHSS评分低于对照组, 差异有统计学意义（P<0.05）.出院3个月后, 观察组患者日常生活能力治疗有效率97.06%明显高于对照组的70.59%, 差异有统计学意义（P<0.05）.结论 醒脑静联合尼莫地平治疗HCH患者具有较好的治疗效果, 还可改善患者的神经缺损功能, 值得推广.
【关键词】 高血压脑出血；醒脑静；尼莫地平；美国国立卫生研究院卒中量表；日常生活能力量表
DOI：10.14163/j.cnki.11-5547/r.2018.13.059
【Abstract】 Objective To study the effect of Xingnaojing combined with nimodipine on National Institutes of Health Stroke scale （NIHSS） and activity of daily living scale （ADL） scores in patients with hypertensive cerebral hemorrhage （HCH）. Methods A total of 68 HCH patients were randomly divided into control group and observation group, with 34 cases in each group. The control group received Xingnaojing for conventional therapy, and the observation group received Xingnaojing combined with nimodipine for treatment. After 4 weeks of treatment, comparison were made on NIHSS score before and after treatment and daily living
3 months after discharge between the two groups. Results After 4 weeks of treatment, the observation group had lower NIHSS score as （6.92±6.84） points than （17.51±3.26） points before treatment, and the control group had lower NIHSS score as （11.42±7.31） points than （17.60±2.73） points than before treatment. The observation group had lower NIHSS score than the control group, and their difference was statistically significant （P<0.05）. 3 months after discharge, the observation group had obviously higher treatment effective rate of activity of daily living as 97.06% than 70.59% in the control group, and the difference was statistically significant （P<0.05）. Conclusion Combination of Xingnaojing and nimodipine shows good treatment effect in treating HCH patients, and it can improve the neurological deficits, and it is worthy of promotion.
【Key words】 Hypertensive cerebral hemorrhage； Xingnaojing； Nimodipine； National Institutes of Health Stroke scale； Activity of daily living scale
高血壓脑出血（hypertensive cerebral hemorrhage, HCH）在我国是一种致残率、死亡率及发病率均较高的脑血管的疾病.HCH是高血压病最为严重的并发症之一, 常发生于50～70岁, 男性略多, 且冬春季易发.高血压病常会导致脑底的小动脉发生病理性变化, 突出的表现是在此类小动脉的管壁上发生玻璃样或纤维样变性和局灶性出血、缺血和坏死, 削弱了血管壁的强度, 出现局限性的扩张, 并可形成微小动脉瘤[1].因情绪激动、过度脑力和体力劳动或其他因素引起血压剧烈升高, 导致已病变的脑血管破裂出血, 最终引发HCH.有研究调查发现[2, 3], 用醒脑静及尼莫地平联合治疗对HCH的治疗有较好的治疗结果, 为进一步证实醒脑静及尼莫地平的联合对HCH患者治疗的有效性, 本文对34例HCH患者进行醒脑静及尼莫地平的联合治疗, 得到较好的结果.现报告如下.
尼莫地平论文参考资料：
结论：醒脑静联合尼莫地平对高血压脑出血患者NIHSSADL评分影响为关于对不知道怎么写尼莫地平论文范文课题研究的大学硕士、相关本科毕业论文尼莫地平停药会反弹吗论文开题报告范文和文献综述及职称论文的作为参考文献资料下载。
